<DOC>
	<DOCNO>NCT02436577</DOCNO>
	<brief_summary>This study open-label , randomise , three-period , three-treatment , crossover study healthy Japanese male female non-childbearing potential subject , perform single study centre . The objective study assess bioequivalence ticagrelor orodispersible ( OD ) tablet administered water without water ticagrelor immediate-release ( IR ) tablet .</brief_summary>
	<brief_title>Study Assess Bioequivalence Between Ticagrelor Orodispersible Tablets Ticagrelor Immediate-release Tablets Japanese Subjects</brief_title>
	<detailed_description>Study evaluate bioequivalence ticagrelor orodispersible ( OD ) tablet administered water without water ticagrelor immediate-release ( IR ) tablet .</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male female subject age 20 45 year suitable vein cannulation repeat venepuncture . Be Japanese . Japanese define parent four grandparent Japanese . This include second third generation Japanese whose parent grandparent live country Japan . Females must negative pregnancy test screen admission clinical unit , must lactate , must nonchildbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment FSH level postmenopausal range . Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . Have body mass index ( BMI ) 18.0 27.0 kg/m2 inclusive weigh least 45 kg 85 kg inclusive . Be able willing communicate investigator comply study procedure , include reproductive restriction . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . Current smoker smoke used nicotine product within previous 3 month . History hemophilia , von Willebrand 's disease , lupus anticoagulant , diseases/syndromes either alter increase propensity bleed . A personal history vascular abnormality include aneurysm ; personal history severe hemorrhage , hematemesis , melena , hemoptysis , severe epistaxis , severe thrombocytopenia , intracranial hemorrhage ; rectal bleeding within 1 year prior screening ; history suggestive peptic ulcer disease ; discretion investigator . History clinically significant nontraumatic bleed clinically significant bleeding risk , judge investigator . Use aspirin , ibuprofen , nonsteroidal antiinflammatory drug ( NSAIDs ) , drug know increase propensity bleed 2 week randomization . Platelet count le 150 x 10^9/L .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ticagrelor orodispersible tablet</keyword>
	<keyword>ticagrelor immediate-release tablet</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy Japanese subject</keyword>
</DOC>